A biomarker could help identify patients with lung cancer who are most likely to benefit from treatment with AstraZeneca and Daiichi Sankyo's TROP2-directed drug datopotamab deruxtecan (Dato-DXd). The ...
AstraZeneca and Daiichi Sankyo have moved swiftly to file for FDA approval of a second indication for their TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), this time for ...
DXD Fund Profile ProShares Trust - ProShares UltraShort Dow30 is an exchange traded fund launched and managed by ProShare Advisors LLC. It invests in public equity markets of the United States. The ...
Is VMEO a buy now? Chart does not reflect overnight price.
At close: December 5 at 4:00:00 PM EST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results